查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1378710

運輸甲狀腺素蛋白心肌病樣心肌病變 (ATTR-CM) 治療市場：按類型、按藥物類型、按配銷通路、按地區

Transthyretin Amyloid Cardiomyopathy Treatment Market, By Type, By Drug Type, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，轉甲狀腺素蛋白澱粉樣心肌病（ATTR-CM）治療的全球市場規模預計為16.9億美元，預測期內（2023-2030年）年複合成長率為31.1%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 16.9億美元
實績資料 2018-2021 預測期 2023-2030
預測期年複合成長率 31.10% 2030年市場規模預測 112.3億美元
圖 1. 轉甲狀腺素蛋白澱粉樣心肌病(ATTR-CM) 治療的全球市場佔有率(%)（按類型），2023 年
運甲狀腺素蛋白澱粉樣心肌病變治療市場-IMG1

運甲狀腺素蛋白澱粉樣心肌病（ATTR-CM）是一種罕見且嚴重的疾病，其特徵是運甲狀腺素蛋白在心臟中異常積累，可導致嚴重的心肌病和心臟衰竭。這些蛋白質沉積物會干擾心肌的正常功能，使其變得更僵硬，泵血效率降低。

ATTR-CM 通常是一種進行性、危及生命的疾病，主要影響老年人，但也可能出現影響年輕人的遺傳形式。

ATTR-CM 的治療是一個複雜且不斷發展的領域，雖然尚無治療方法，但有幾種治療方法旨在控制症狀、減緩疾病進展並改善患者的生活品質。這些治療方法包括旨在穩定轉甲狀腺素蛋白、減輕心臟衰竭症狀和減少心臟澱粉樣蛋白沉積負擔的藥物。在某些情況下，心臟移植可被視為一種治療選擇。

市場動態

全球轉甲狀腺素蛋白澱粉樣心肌病(ATTR-CM) 治療市場的成長是由不斷探索創新治療方法的研究推動的，包括基因靜默療法和針對疾病根本原因的新型藥物，並由臨床試驗推動。例如，2020年總公司，美國製藥公司Alexion在日本有症狀的ATTR-CM受試者中評估了ALXN2060（也稱為AG10）的有效性、安全性和耐受性，並已開始一項3期研究，以確定其藥物動力學和耐受性。動態概況。新的市場進入預計將進一步擴大臨床管線並推動全球轉甲狀腺素蛋白型澱粉樣心肌病（ATTR-CM）治療市場的成長。

本研究的主要特點

  • 本報告對運輸甲狀腺素蛋白澱粉樣心肌病（ATTR-CM）治療市場進行了詳細分析，並介紹了以 2022 年為基準年的預測期（2023-2030）的市場規模和年複合成長率。
  • 它還闡明了各個細分市場的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
  • 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 根據公司亮點、產品系列、主要亮點、業績和策略等參數，對轉甲狀腺素蛋白型澱粉樣心肌病(ATTR-CM) 治療市場的主要企業進行了分析。
  • 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
  • 全球轉甲狀腺素蛋白澱粉樣心肌病(ATTR-CM) 治療市場報告面向該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進入者和財務分析師。
  • 透過用於分析全球轉甲狀腺素蛋白澱粉樣心肌病（ATTR-CM）治療市場的各種策略矩陣，將有助於相關人員做出決策。

目錄

第1章 調查目的和假設

  • 這項研究的目的
  • 假設
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章 市場動態、法規及趨勢分析

    • 市場動態
  • 促進因素
  • 抑制因素
  • 市場機會
    • 影響分析
    • 最近的產品核准/發布
    • 合併、收購和合作
    • 法規場景
    • 最近的趨勢
    • 價格分析
    • 主要進展
    • PEST分析
    • 波特的分析

第4章 全球轉甲狀腺素蛋白澱粉樣心肌病（ATTR-CM）治療市場－新型冠狀病毒感染疾病（COVID-19）的影響分析

    • 經濟影響
    • 新型冠狀病毒感染疾病（COVID-19）的流行病學
    • 對需求和供給的影響

第5章 全球運輸甲狀腺素蛋白澱粉樣心肌病（ATTR-CM）治療市場，按類型，2018-2030

  • 遺傳性轉甲狀腺素蛋白類澱粉蛋白沉積症(hATTR)
  • 野生型轉甲狀腺素蛋白類澱粉蛋白沉積症(wtATTR)

第6章 全球運輸甲狀腺素蛋白澱粉樣心肌病（ATTR-CM）治療市場，依藥物類型，2018-2030

  • 運輸甲狀腺素蛋白穩定劑
  • 非類固醇消炎劑(NSAID)
  • RNAi療法
  • 其他

第7章 全球轉甲狀腺素蛋白澱粉樣心肌病（ATTR-CM）治療市場，依配銷通路，2018-2030

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球運輸甲狀腺素蛋白澱粉樣心肌病（ATTR-CM）治療市場，按地區，2018-2030

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中東
  • GCC
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章 競爭形勢

  • 公司簡介
    • Pfizer Inc.
    • GlaxoSmithKline Plc.
    • Eidos Therapeutics
    • Ionis Pharmaceuticals, Inc.
    • Alnylam Pharmaceuticals
    • Prothena Corporation plc
    • Intellia Therapeutics, Inc.
    • Corino Therapeutics, Inc.
  • 分析師觀點

第10章 章

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI4321

Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is estimated to be valued at US$ 1.69 Bn in 2023, and is expected to exhibit a CAGR of 31.1% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 1.69 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 31.10% 2030 Value Projection: US$ 11.23 Bn
Figure 1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Share (%), By Type, 2023
Transthyretin Amyloid Cardiomyopathy Treatment Market - IMG1

Transthyretin amyloid ardiomyopathy (ATTR-CM) is a rare and serious medical condition characterized by the abnormal accumulation of transthyretin protein deposits in the heart that can lead to severe cardiomyopathy and heart failure. These protein deposits disrupt the normal functioning of the heart muscle, and causes it to become stiff and less effective in pumping blood. ATTR-CM is often a progressive and life-threatening disease that primarily affects older adults, but it can also manifest in a hereditary form that affects individuals at a younger age.

The treatment of ATTR-CM is a complex and evolving field. While there is no cure for the condition, several therapeutic approaches aim to manage symptoms, slow the progression of the disease, and improve the patient's quality of life. These treatment options can include medications designed to stabilize transthyretin proteins, alleviate heart failure symptoms, and reduce the burden of amyloid deposits in the heart. In some cases, heart transplantation may be considered as a treatment option.

Market Dynamics

Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth is driven by ongoing research and clinical trials that are exploring innovative treatments including gene-silencing therapies and novel medications that targets the underlying causes of the disease. For instance, in November 2020, Alexion, Inc., a U.S.-based pharmaceutical company, initiated a phase 3 study that evaluates the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), and to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM. With the entrance of new players in the market, the clinical pipeline is expected to expand further driving the growth of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Key features of the study:

  • This report provides an in-depth analysis of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Detailed Segmentation:

  • By Type:
    • Hereditary Transthyretin Amyloidosis (hATTR)
    • Wild Type Transthyretin Amyloidosis (wtATTR)
  • By Drug Type:
    • Transthyretin Stabilizers
    • Nonsteroidal Anti-inflammatory Drugs (NSAID)
    • Rnai Therapy
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles
    • Pfizer Inc.
    • GlaxoSmithKline Plc.
    • Eidos Therapeutics
    • Ionis Pharmaceuticals, Inc.
    • Alnylam Pharmaceuticals
    • Prothena Corporation plc
    • Intellia Therapeutics, Inc.
    • Corino Therapeutics, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Type
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Recent Product Approvals/Launches
    • Mergers, Acquisitions, and Collaborations
    • Regulatory Scenario
    • Recent Trends
    • Pricing Analysis
    • Key Developments
    • PEST Analysis
    • Porter's Analysis

4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - COVID-19 Impact Analysis

    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand

5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hereditary Transthyretin Amyloidosis (hATTR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Segment Trends
  • Wild Type Transthyretin Amyloidosis (wtATTR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Segment Trends

6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Transthyretin Stabilizers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Segment Trends
  • Nonsteroidal Anti-inflammatory Drugs (NSAID)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Segment Trends
  • RNAi Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Segment Trends

7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Segment Trends
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Segment Trends
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Segment Trends

8. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • Pfizer Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • GlaxoSmithKline Plc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Eidos Therapeutics
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Ionis Pharmaceuticals, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Alnylam Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Prothena Corporation plc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Intellia Therapeutics, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Corino Therapeutics, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
  • Analysts' Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact